This line of research studies:

• Prognostic factors in the antiviral treatment of chronic hepatitis C: 

Viral: genotype, viral load and genomic variability

Host: immunogenetic factors (HLA polymorphisms, NK receptors, cytokines and IL28B

• Pharmacokinetic and pharmacodynamic studies

Ribavirin and pegylated interferon, Telaprevir, Boceprevir and 2nd generation treatments

• Studies of the vertical transmission of VHC

Genomic variability of VHC and immunogenetic factors of mother and child (HLA and IL28B)